Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Cancer|2011Cited by 28
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulationSilvia L. Locatelli, Carmelo Carlo‐Stella|Scientific Reports|2016Cited by 21
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAMLiliana Devizzi, Alessandro M. Gianni, Ettore Seregni et al.|Journal of Clinical Oncology|2013Cited by 14
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartmentChiara Lobetti‐Bodoni, Marco Ladetto, Dario Ferrero et al.|Mechanisms of Ageing and Development|2012Cited by 9
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.Anna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Blood|2010Cited by 1